Cardio Diagnostics Holdings (NASDAQ: CDIO) is harnessing artificial intelligence, epigenetics, and genetics to improve early detection and diagnosis of coronary heart disease through its blood-based Epi+Gen CHD and PrecisionCHD tests. The company addresses a cardiovascular disease market projected to grow from $393 billion in annual healthcare costs in 2020 to $1.4 trillion by 2050, according to the press release.
Cardio Diagnostics’ proprietary AI-driven Multi-Omics Engine analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including certain nonobstructive forms that conventional diagnostic methods may miss. This approach allows for more precise and personalized cardiovascular care, potentially improving patient outcomes and reducing healthcare costs.
To further its reach, Cardio Diagnostics has secured finalized CMS reimbursement rates and dedicated CPT laboratory codes, expanded U.S. provider partnerships, and launched its first international expansion in India. These developments strengthen the company’s commercialization efforts and position it for growth in the diagnostics landscape.
The company’s proprietary, AI-driven platform, combined with reimbursement milestones and growing provider adoption, provides a scientifically grounded and commercially actionable position. Evidence supporting the ability to detect what traditional tools miss adds to the company’s potential impact on cardiovascular disease management.
For more information about Cardio Diagnostics, visit https://cdio.ai/. To view the full article, see https://nnw.fm/9LJ2r.
